Cart
0

Biopharmaceuticals Market By Type (Monoclonal Antibody, Interferon, Insulin, Growth & Coagulation Factor, Erythropoietin, Vaccine, Hormone, and, Others) and Application (Oncology, Blood Disorder, Metabolic Disease, Infectious Disease, Cardiovascular Disease, Neurological Disease, Immunology, and Others) - Global Opportunity Analysis And Industry Forecast, 2018-2025

Get 20% Free Customization In This Report
LI_183971
Pages: 255
Jul 2018 | 1977 Views
 
Author's : Sohail Shaikh & Pallavi Jaiswal
Tables: 101
Charts: 58
 

Biopharmaceuticals Market Overview:

The global biopharmaceuticals market accounted for $186,470 million in 2017, and is projected to reach $526,008 million by 2025, registering a CAGR of 13.8% from 2018 to 2025. Biopharmaceuticals are substances that are produced using living organisms, such as microorganisms and animal cells, and have a high-therapeutic value. These large and complex molecular drugs are also known as biologics and biotech drugs.

The global biopharmaceuticals market is driven by various factors, such as increase in elderly population, surge in prevalence of chronic diseases such as cancer and diabetes, and increase in adoption of biopharmaceuticals globally. Furthermore, rise in strategic collaborations among biopharmaceuticals companies is also anticipated to supplement the growth of the biopharmaceuticals industry.

However, high costs associated with drug development and their threat of failure are factors anticipated to restrain the growth of the global biopharmaceuticals market. Conversely, emerging economies, such as India and China, are anticipated to provide lucrative growth opportunities to the key players involved for business expansion in the global biopharmaceuticals market during the forecast period.

The global biopharmaceuticals market is segmented based on type, application, and region. On the basis of type, the market is divided into monoclonal antibody, interferon, insulin, growth and coagulation factor, erythropoietin, vaccine, hormone, and others. By application, it is categorized into oncology, blood disorder, metabolic disease, infectious disease, cardiovascular disease, neurological disease, immunology, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America Middle East and Africa (LAMEA).

Get more information on this report : Request Sample Pages

The monoclonal antibody segment dominated the global biopharmaceuticals market in 2017, owing to the wide adoption of these drugs to treat chronic diseases, such as cancer. Furthermore, surge in R&D with respect to oncology drug development is also anticipated to boost the biopharmaceuticals market for monoclonal antibodies.

Get more information on this report : Request Sample Pages

Rise in focus of vendors on the emerging markets, such as Asia-Pacific and LAMEA, is expected to boost the market growth. The Asia-Pacific region is projected to witness significant growth in future, owing to increase in R&D investment, rise in adoption and availability of biopharmaceuticals for disease treatment and surge in disease diagnosis awareness. Furthermore, this region presents remarkable opportunities for venture capitalists and investors, because the developed markets are comparatively saturated.

The report provides an extensive competitive analysis and profiles of the key market players, such as Abbott Laboratories, Amgen, Inc., Biogen, Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Ltd., Johnson & Johnson, Merck & Co., Inc., Novo Nordisk A/S, Pfizer, Inc., and Sanofi. The other players in the value chain (not included in the report) include Bristol Myers Squibb Company, Bayer AG, and Shire plc.

Key Benefits

  • The study provides an in-depth analysis of the global biopharmaceuticals market along with the current trends and future estimations to elucidate the imminent investment pockets of the global biopharmaceuticals industry.
  • The report presents a quantitative analysis of the biopharmaceuticals market from 2017 to 2025 to enable stakeholders to capitalize on the prevailing market opportunities.
  • An extensive analysis of the biopharmaceuticals market based on type and application assists in understanding the trends in the global biopharmaceuticals industry.
  • The key market players along with their strategies are thoroughly analyzed to understand the competitive outlook of the biopharmaceuticals industry.

Biopharmaceuticals Market Key Segments:

By product

  • Monoclonal antibody
  • Interferon
  • Insulin
  • Growth and coagulation factor
  • Erythropoietin
  • Vaccine
  • Hormone
  • Others

By application

  • Oncology
  • Blood disorder
  • Metabolic disease
  • Infectious disease
  • Cardiovascular disease
  • Neurological disease
  • Immunology
  • Others

By geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

Chapter: 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.1.1. CXO perspective

Chapter: 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Market Share Analysis, 2017
3.4. Clinical trials
3.5. Patent analysis, 2014-2018

3.5.1. Patent analysis, by year (2014-2018)
3.5.2. Patent analysis, by country

3.6. Market dynamics

3.6.1. Drivers

3.6.1.1. Increase in prevalence of chronic diseases
3.6.1.2. Rise in geriatric population and improvement in healthcare infrastructure
3.6.1.3. Increase in strategic acquisitions and collaborations

3.6.2. Restraints

3.6.2.1. High cost of drug development and threat of failure
3.6.2.2. Stringent regulatory scenario

3.6.3. Opportunity

3.6.3.1. Increase in purchasing power of emerging economics

Chapter: 4: BIOPHARMACEUTICALS MARKET, BY TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Monoclonal Antibodies

4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Interferons

4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Insulin

4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Growth and coagulation factors

4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

4.6. Erythropoietin

4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

4.7. Vaccines

4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country

4.8. Hormones

4.8.1. Key market trends, growth factors and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis, by country

4.9. Other

4.9.1. Key market trends, growth factors and opportunities
4.9.2. Market size and forecast, by region
4.9.3. Market analysis, by country

Chapter: 5: BIOPHARMACEUTICALS MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Oncology

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. Blood Disorders

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

5.4. Metabolic Diseases

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

5.5. Infectious Diseases

5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country

5.6. Cardiovascular Diseases

5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country

5.7. Neurological Diseases

5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by country

5.8. Immunology

5.8.1. Market size and forecast, by region
5.8.2. Market analysis, by country

5.9. Other Applications

5.9.1. Market size and forecast, by region
5.9.2. Market analysis, by country

Chapter: 6: BIOPHARMACEUTICALS MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America Biopharmaceuticals market size and forecast, by country

6.2.2.1. U.S. market size and forecast

6.2.2.1.1. U.S. Biopharmaceuticals market, by type
6.2.2.1.2. U.S. Biopharmaceuticals market, by application

6.2.2.2. Canada market size and forecast

6.2.2.2.1. Canada Biopharmaceuticals market, by type
6.2.2.2.2. Canada Biopharmaceuticals market, by application

6.2.2.3. Mexico market size and forecast

6.2.2.3.1. Mexico Biopharmaceuticals market, by type
6.2.2.3.2. Mexico Biopharmaceuticals market, by application

6.2.3. North America Biopharmaceuticals market size and forecast, by type
6.2.4. North America Biopharmaceuticals market size and forecast, by application

6.3. Europe

6.3.1. Key market trends, growth factors and opportunities
6.3.2. Europe Biopharmaceuticals market size and forecast, by country

6.3.2.1. Germany market size and forecast

6.3.2.1.1. Germany. Biopharmaceuticals market, by type
6.3.2.1.2. Germany Biopharmaceuticals market, by application

6.3.2.2. France market size and forecast

6.3.2.2.1. France Biopharmaceuticals market, by type
6.3.2.2.2. France Biopharmaceuticals market, by application

6.3.2.3. UK market size and forecast

6.3.2.3.1. UK Biopharmaceuticals market, by type
6.3.2.3.2. UK Biopharmaceuticals market, by application

6.3.2.4. Italy market size and forecast

6.3.2.4.1. Italy Biopharmaceuticals market, by type
6.3.2.4.2. Italy Biopharmaceuticals market, by application

6.3.2.5. Spain market size and forecast

6.3.2.5.1. Spain. Biopharmaceuticals market, by type
6.3.2.5.2. Spain Biopharmaceuticals market, by application

6.3.2.6. Rest of Europe market size and forecast

6.3.2.6.1. Rest of Europe Biopharmaceuticals market, by type
6.3.2.6.2. Rest of Europe Biopharmaceuticals market, by application

6.3.3. Europe Biopharmaceuticals market size and forecast, by type
6.3.4. Europe Biopharmaceuticals market size and forecast, by application

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors and opportunities
6.4.2. Asia-Pacific Biopharmaceuticals market size and forecast, by country

6.4.2.1. Japan market size and forecast

6.4.2.1.1. Japan Biopharmaceuticals market, by type
6.4.2.1.2. Japan Biopharmaceuticals market, by application

6.4.2.2. China market size and forecast

6.4.2.2.1. China Biopharmaceuticals market, by type
6.4.2.2.2. China Biopharmaceuticals market, by application

6.4.2.3. India market size and forecast

6.4.2.3.1. India Biopharmaceuticals market, by type
6.4.2.3.2. India Biopharmaceuticals market, by application

6.4.2.4. Australia market size and forecast

6.4.2.4.1. Australia Biopharmaceuticals market, by type
6.4.2.4.2. Australia Biopharmaceuticals market, by application

6.4.2.5. South Korea market size and forecast

6.4.2.5.1. South Korea Biopharmaceuticals market, by type
6.4.2.5.2. South Korea Biopharmaceuticals market, by application

6.4.2.6. Rest of Asia-Pacific market size and forecast

6.4.2.6.1. Rest of Asia-Pacific Biopharmaceuticals market, by type
6.4.2.6.2. Rest of Asia-Pacific Biopharmaceuticals market, by application

6.4.3. Asia-Pacific Biopharmaceuticals market size and forecast, by type
6.4.4. Asia-Pacific Biopharmaceuticals market size and forecast, by application

6.5. LAMEA

6.5.1. Key market trends, growth factors and opportunities
6.5.2. LAMEA Biopharmaceuticals market size and forecast, by country

6.5.2.1. Brazil market size and forecast

6.5.2.1.1. Brazil Biopharmaceuticals market, by type
6.5.2.1.2. Brazil Biopharmaceuticals market, by application

6.5.2.2. Saudi Arabia market size and forecast

6.5.2.2.1. Saudi Arabia. Biopharmaceuticals market, by type
6.5.2.2.2. Saudi Arabia Biopharmaceuticals market, by application

6.5.2.3. South Africa market size and forecast

6.5.2.3.1. South Africa Biopharmaceuticals market, by type
6.5.2.3.2. South Africa Biopharmaceuticals market, by application

6.5.2.4. Rest of LAMEA market size and forecast

6.5.2.4.1. Rest of LAMEA Biopharmaceuticals market, by type
6.5.2.4.2. Rest of LAMEA Biopharmaceuticals market, by application

6.5.3. LAMEA Biopharmaceuticals market size and forecast, by type
6.5.4. LAMEA Biopharmaceuticals market size and forecast, by application

Chapter: 7: COMPANY PROFILES

7.1. Abbott Laboratories

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance

7.2. Amgen Inc.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments

7.3. Biogen Inc.

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments

7.4. Eli Lilly and Company

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. F. Hoffmann-La Roche Ltd.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. Johnson & Johnson

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. Merck & Co., Inc.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. Novo Nordisk A/S

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments

7.9. Pfizer Inc.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments

7.10. Sanofi

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments

LIST OF TABLES

TABLE 01. COMPLETED CLINICAL TRIALS IN BIOPHARMACEUTICALS MARKET
TABLE 02. GLOBAL BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 03. KEY MONOCLONAL ANTIBODIES
TABLE 04. MONOCLONAL ANTIBODIES BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 05. INTERFERONS BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 06. INSULIN BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 07. GROWTH AND COAGULATION FACTORS BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 08. ERYTHROPOIETIN BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 09. VACCINES BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 10. HORMONES BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 11. OTHER BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 12. GLOBAL BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 13. CANCER: KEY BIOPHARMACEUTICALS
TABLE 14. ONCOLOGY BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 15. BLOOD DISORDERS: KEY BIOPHARMACEUTICALS
TABLE 16. BLOOD DISORDERS BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 17. METABOLIC DISEASES BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 18. INFECTIOUS DISEASES BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 19. CARDIOVASCULAR DISEASES BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 20. NEUROLOGICAL DISEASES BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 21. IMMUNOLOGY BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 22. OTHER APPLICATIONS BIOPHARMACEUTICALS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 23. BIOPHARMACEUTICALS MARKET REVENUE, BY REGION, 2017-2025 ($MILLION)
TABLE 24. NORTH AMERICA BIOPHARMACEUTICALS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 25. U.S. BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 26. U.S. BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 27. CANADA BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 28. CANADA BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 29. MEXICO BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 30. MEXICO BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 31. NORTH AMERICA BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 32. NORTH AMERICA BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 33. EUROPE BIOPHARMACEUTICALS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 34. GERMANY BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 35. GERMANY BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 36. FRANCE BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 37. FRANCE BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 38. UK BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 39. UK BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 40. ITALY BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 41. ITALY BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 42. SPAIN BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 43. SPAIN BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 44. REST OF EUROPE BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 45. REST OF EUROPE BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 46. EUROPE BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 47. EUROPE BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 48. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 49. JAPAN BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 50. JAPAN BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 51. CHINA BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 52. CHINA BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 53. INDIA BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 54. INDIA BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 55. AUSTRALIA BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 56. AUSTRALIA BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 57. SOUTH KOREA BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 58. SOUTH KOREA BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 59. REST OF ASIA-PACIFIC BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 60. REST OF ASIA-PACIFIC BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 61. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 62. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 63. LAMEA BIOPHARMACEUTICALS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 64. BRAZIL. BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 65. BRAZIL BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 66. SAUDI ARABIA BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 67. SAUDI ARABIA BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 68. SOUTH AFRICA BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 69. SOUTH AFRICA BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 70. REST OF LAMEA BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 71. REST OF LAMEA BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 72. LAMEA BIOPHARMACEUTICALS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 73. LAMEA BIOPHARMACEUTICALS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 74. ABBOTT: COMPANY SNAPSHOT
TABLE 75. ABBOTT: OPERATING SEGMENTS
TABLE 76. ABBOTT: PRODUCT PORTFOLIO
TABLE 77. AMGEN: COMPANY SNAPSHOT
TABLE 78. AMGEN: PRODUCT PORTFOLIO
TABLE 79. BIOGEN: COMPANY SNAPSHOT
TABLE 80. BIOGEN: PRODUCT PORTFOLIO
TABLE 81. LILLY: COMPANY SNAPSHOT
TABLE 82. LILLY: OPERATING SEGMENTS
TABLE 83. LILLY: PRODUCT PORTFOLIO
TABLE 84. ROCHE: COMPANY SNAPSHOT
TABLE 85. ROCHE: OPERATING SEGMENTS
TABLE 86. ROCHE: PRODUCT PORTFOLIO
TABLE 87. J&J: COMPANY SNAPSHOT
TABLE 88. J&J: OPERATING SEGMENTS
TABLE 89. J&J: PRODUCT PORTFOLIO
TABLE 90. MERCK: COMPANY SNAPSHOT
TABLE 91. MERCK: OPERATING SEGMENTS
TABLE 92. MERCK: PRODUCT PORTFOLIO
TABLE 93. NOVO NORDISK: COMPANY SNAPSHOT
TABLE 94. NOVO NORDISK: OPERATING SEGMENTS
TABLE 95. NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 96. PFIZER: COMPANY SNAPSHOT
TABLE 97. PFIZER: OPERATING SEGMENTS
TABLE 98. PFIZER: PRODUCT PORTFOLIO
TABLE 99. SANOFI: COMPANY SNAPSHOT
TABLE 100. SANOFI: OPERATING SEGMENTS
TABLE 101. SANOFI: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. BIOPHARMACEUTICALS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2014-2018*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2014-2018* (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2014-2018*
FIGURE 06. MARKET SHARE ANALYSIS, 2017
FIGURE 07. PATENT REGISTERED/APPROVED, BY YEAR
FIGURE 08. PATENT REGISTERED, BY COUNTRY
FIGURE 09. BIOPHARMACEUTICALS MARKET: IMPACT ANALYSES
FIGURE 10. DIABETES BURDEN: KEY TAKEAWAYS
FIGURE 11. GLOBAL ELDERLY POPULATION (AGED 65 AND ABOVE), BY REGION (2015, 2030, AND 2050)
FIGURE 12. COMPARATIVE COUNTRY ANALYSIS OF MONOCLONAL ANTIBODIES BIOPHARMACEUTICALS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 13. COMPARATIVE COUNTRY ANALYSIS OF INTERFERONS BIOPHARMACEUTICALS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 14. COMPARATIVE COUNTRY ANALYSIS OF INSULIN BIOPHARMACEUTICALS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 15. COMPARATIVE COUNTRY ANALYSIS OF GROWTH AND COAGULATION FACTORS BIOPHARMACEUTICALS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 16. COMPARATIVE COUNTRY ANALYSIS OF ERYTHROPOIETIN BIOPHARMACEUTICALS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 17. COMPARATIVE COUNTRY ANALYSIS OF VACCINES BIOPHARMACEUTICALS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 18. COMPARATIVE COUNTRY ANALYSIS OF HORMONES BIOPHARMACEUTICALS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 19. COMPARATIVE COUNTRY ANALYSIS OF OTHER BIOPHARMACEUTICALS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 20. COMPARATIVE COUNTRY ANALYSIS OF ONCOLOGY BIOPHARMACEUTICALS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 21. COMPARATIVE COUNTRY ANALYSIS OF BLOOD DISORDERS BIOPHARMACEUTICALS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 22. COMPARATIVE COUNTRY ANALYSIS OF METABOLIC DISEASES BIOPHARMACEUTICALS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 23. HEPATITIS: KEY FACTS
FIGURE 24. COMPARATIVE COUNTRY ANALYSIS OF INFECTIOUS DISEASES BIOPHARMACEUTICALS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 25. COMPARATIVE COUNTRY ANALYSIS OF CARDIOVASCULAR DISEASES BIOPHARMACEUTICALS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 26. COMPARATIVE COUNTRY ANALYSIS OF NEUROLOGICAL DISEASES BIOPHARMACEUTICALS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 27. COMPARATIVE COUNTRY ANALYSIS OF IMMUNOLOGY BIOPHARMACEUTICALS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 28. COMPARATIVE COUNTRY ANALYSIS OF OTHER APPLICATIONS BIOPHARMACEUTICALS MARKET, 2017 AND 2025 ($MILLION)
FIGURE 29. ABBOTT: NET SALES, 2015-2017 ($MILLION)
FIGURE 30. ABBOTT: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 31. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 32. AMGEN: NET SALES, 2015-2017 ($MILLION)
FIGURE 33. AMGEN: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 34. AMGEN: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 35. BIOGEN: REVENUE, 2015-2017 ($MILLION)
FIGURE 36. BIOGEN: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 37. BIOGEN: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 38. LILLY: NET SALES, 2015-2017 ($MILLION)
FIGURE 39. LILLY: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 40. LILLY: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 41. ROCHE: NET SALES, 2015-2017 ($MILLION)
FIGURE 42. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 43. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 44. J&J: NET SALES, 2015-2017 ($MILLION)
FIGURE 45. J&J: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 46. J&J: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 47. MERCK: NET SALES, 2015-2017 ($MILLION)
FIGURE 48. MERCK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 49. MERCK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 50. NOVO NORDISK: NET SALES, 2015-2017 ($MILLION)
FIGURE 51. NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 52. NOVO NORDISK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 53. PFIZER: NET SALES, 2015-2017 ($MILLION)
FIGURE 54. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 55. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 56. SANOFI: NET SALES, 2015-2017 ($MILLION)
FIGURE 57. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 58. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

 

Biopharmaceuticals have positively affected diverse fields of disease treatment and prognosis. Diseases that were otherwise debilitating and life-threatening are managed through administration of these drugs. The demand for biopharmaceuticals products has increased considerably, owing to increase in prevalence of chronic diseases, such as cancer and diabetes, in both developed and developing economies.

The key factors, such as increase in prevalence of obesity and rise of sedentary lifestyle in the populace, boost the biopharmaceuticals market globally. Furthermore, increase in awareness about biopharmaceuticals products and surge in strategic collaborations among biopharmaceutical companies are anticipated to drive the market growth during the forecast period.

However, high treatment costs per patient, stringent government regulations towards biopharmaceuticals, and high costs associated with drug development restrict the market growth. The use of biopharmaceuticals modalities is highest in North America, owing to availability of biopharmaceuticals products, surge in R&D, and rise in expenditure by the government on healthcare, followed by Europe and Asia-Pacific. In addition, biopharmaceuticals companies have focused on expanding their presence in the emerging economies, which is anticipated to drive the market growth.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Biopharmaceuticals Market- Global Opportunity Analysis And Industry Forecast, 2018-2025

  • Online Only
  • $3456
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $8995
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo